Element Biosciences vs Neuralink
Side-by-side comparison of AI visibility scores, market position, and capabilities
Element Biosciences makes the AVITI benchtop DNA sequencer; raised $277M Series D in 2024 (led by Wellington Management, Samsung) for $680M+ cumulative; install base grew from ~40 to 190+ units in 12 months.
About
Element Biosciences is a genomics company developing next-generation DNA sequencing instruments and reagents designed to democratize access to high-quality, cost-effective sequencing. Founded in 2017 by veterans from Illumina, Life Technologies, and other genomics leaders, the company is headquartered in San Diego, California. Its flagship product, the AVITI System, is a benchtop sequencer that combines high accuracy, flexible throughput, and competitive per-sample costs — making research-grade sequencing accessible to academic labs, biotech companies, agricultural research programs, and clinical settings that previously could not justify large capital outlays for sequencing infrastructure.
Pioneer of implantable BCIs with 12+ active human patients as of Sep 2025; raised $650M Series E in Apr 2026 led by ARK Invest and Sequoia at a ~$14.9B valuation; mass production underway.
About
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with paralysis to control digital devices directly with their thoughts. The company's first commercial product, the N1 implant, is a coin-sized device containing 1,024 electrodes that is surgically placed in the motor cortex. As of September 2025, twelve patients worldwide had received the N1 implant and were actively using it to control computers, smartphones, and robotic arms with neural signals alone.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.